XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 120,914 $ 155,700
Short-term investments 130,426 266,308
Accounts receivable, net ($22,916 and $12,088 from related parties) 31,694 16,299
Inventories 40,696 40,436
Prepaid expenses and other current assets 40,378 14,083
Total current assets 364,108 492,826
Restricted time deposits 2,072 2,072
Long-term investments 0 4,348
Property and equipment, net 14,512 20,605
Equity method investment in unconsolidated variable interest entity 4,534 5,061
Operating lease right-of-use assets 71,248 79,893
Other assets 3,952 5,282
Total assets 460,426 610,087
Current liabilities:    
Accounts payable 19,220 30,758
Accrued and other current liabilities ($29,157 and $63,886 to a related party) 170,986 219,773
Deferred revenue ($5,482 and $9,259 to related parties) 7,325 12,739
Operating lease liabilities, current 11,884 10,292
Total current liabilities 209,415 273,562
Product development obligations 16,942 16,917
Deferred revenue, net of current 154,206 185,722
Operating lease liabilities, non-current 70,035 79,593
Senior secured term loan facilities, non-current 71,666 0
Liability related to sale of future revenues, non-current 49,109 49,333
Other long-term liabilities ($668 and $0 to a related party) 4,255 6,440
Total liabilities 575,628 611,567
Commitments and Contingencies (Note 12)
Redeemable non-controlling interests 21,480 0
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.01 par value; 225,000 shares authorized at September 30, 2023 and December 31, 2022; 98,339 and 94,166 shares issued and outstanding at September 30, 2023 and December 31, 2022 983 942
Additional paid-in capital 1,634,459 1,541,019
Accumulated other comprehensive loss (6,923) (5,720)
Accumulated deficit (1,785,688) (1,557,688)
Total stockholders' deficit attributable to FibroGen (157,169) (21,447)
Nonredeemable non-controlling interests 20,487 19,967
Total deficit (136,682) (1,480)
Total liabilities, redeemable non-controlling interests and deficit $ 460,426 $ 610,087